Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Analyst Coverage
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Independent Directors
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

Mar 22, 2022

Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting

Mar 15, 2022

Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update

Feb 11, 2022

Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022

Feb 4, 2022

Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells

Feb 3, 2022

Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma

Jan 12, 2022

Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

Jan 5, 2022

Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021

Dec 7, 2021

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

Nov 30, 2021

Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society for Neuro-oncology Annual Meeting

Nov 18, 2021
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...32
    © 2022 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences